Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TA-46 (Recifercept) in Healthy Volunteers
NCT04410809Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2018
- Primary completion
- Nov 2019
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in achondroplasia (ACH) comparing TA-46 with Placebo (2 arms). Primary endpoints: Treatment Emergent Treatment-Related Adverse Events, Clinical Laboratory Abnormalities and 3 more. Started Jan 2018; status: completed.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT04410809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410809.